Detailed information
COMPOSITION:
Each film coated tablet contains: Alfuzosin hydrochloride (retard) 2.5 mg.
Each film coated tablet contains : Alfuzosin hydrochloride (retard) 5 mg.
PROPERTIES:
Alfuzosin is an alpha 1 adreno-receptor blocker. It's readily absorbed after oral administration and peak plasma concentrations generally occur 0,5-3 hours after dose. Alfuzosin is exerted primary in faeces via the bile and half-life plasma elimination of 3-5 hours.
INDICATIONS:
Alfosin is used in the symptomatic treatment of benign prosatatic hyperplasia.
CONTRAINDICATION:
- Hypersensitivity to the drug.
- Patients with aortic or mitral valve stenosis or pulmonary embolism.
- Patients taking beta-blocker,
SIDE EFFECTS:
Dizziness, headache, nausea, constipation, palpitation, incontinence and skin rashes.
PRECAUTIONS:
- Caution should be taken in patients with renal hepatic impairment, angina pectoris and in elderly.
- Alfosin may cause collapse in some patients after first dose, therefore it should be given just before bedtime to reduce the risk.
DRUG INTERACTIONS:
- Combination with alfosin and other alphi - blocker (prazosin, terazosin) should be avoided.
- Combination with alfosin and calcium antagonists (verapamil, nicardipine, diltiazem ) should be avoided because of risk ofhypotensive effects.
DOSAGE AND ADMINISTRATION:
- Tablets should be swallowed without chewing.
- Doses should be reduced in patients with hepatic or renal impairment.
- Dosage: one tablet 2.5 mg three times dai^y increased to 10 mg if necessary (one tablet 5 mg in the morning and evening).
- Patients over 65years old or in treated hypertensive patients, the initial dose should be one tablet of 2.5 mg twice daily and increased to a maximum of one tablet of 5 mg twice daily.
PRESENTATION:
- Boxes of 20 film coated tablets 2.5 mg.
- Boxes of 20 film coated tablets 5 mg. |
